

**HALL CHADWICK**   
MELBOURNE AUDIT

**SUN PHARMA ANZ PTY LTD**

**ABN 17 110 871 826**

**Audited Financial Statements for the year ended 31 March 2021**

**Sun Pharma ANZ Pty Ltd**  
**Directors' report**  
**31 March 2021**

The directors present their report, together with the financial statements, on the company for the year ended 31 March 2021.

**Dividends**

There were no dividends paid, recommended or declared during the current or previous financial year.

**Review of operations**

The profit for the company after providing for income tax amounted to \$7,898,923 (31 March 2020: \$2,611,621).

**Significant changes in the state of affairs**

There were no significant changes in the state of affairs of the company during the financial year.

**Matters subsequent to the end of the financial year**

No matter or circumstance has arisen since 31 March 2021 that has significantly affected, or may significantly affect the company's operations, the results of those operations, or the company's state of affairs in future financial years.

**Likely developments and expected results of operations**

Information on likely developments in the operations of the company and the expected results of operations have not been included in this report because the directors believe it would be likely to result in unreasonable prejudice to the company.

**Environmental regulation**

The company is not subject to any significant environmental regulation under Australian Commonwealth or State law.

**Shares under option**

There were no unissued ordinary shares of the company under option outstanding at the date of this report.

**Shares issued on the exercise of options**

There were no ordinary shares of the company issued on the exercise of options during the year ended 31 March 2021 and up to the date of this report.

**Indemnity and insurance of officers**

The company has indemnified the directors and executives of the company for costs incurred, in their capacity as a director or executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the company paid a premium in respect of a contract to insure the directors and executives of the company against a liability to the extent permitted by the Corporations Act 2001. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

**Indemnity and insurance of auditor**

The company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the company or any related entity against a liability incurred by the auditor.

During the financial year, the company has not paid a premium in respect of a contract to insure the auditor of the company or any related entity.

**Proceedings on behalf of the company**

No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the company, or to intervene in any proceedings to which the company is a party for the purpose of taking responsibility on behalf of the company for all or part of those proceedings.

**Sun Pharma ANZ Pty Ltd**  
**Directors' report**  
**31 March 2021**

**Auditor's independence declaration**

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the Corporations Act 2001.

On behalf of the directors

---

Akshay Sethi  
Head of Finance, Director

Date:

**SUN PHARMA ANZ PTY LTD  
ABN 17 110 871 826**

**AUDITOR'S INDEPENDENCE DECLARATION UNDER  
SECTION 307C OF THE CORPORATIONS ACT 2001**

**TO THE DIRECTORS OF  
SUN PHARMA ANZ PTY LTD**

In accordance with the requirements of section 307C of the Corporations Act 2011, I declare that, to the best of my knowledge and belief, for the year ended 31 March 2021 there have been:

- (i) No contraventions of the auditor independence requirements as set out in the Corporations Act 2001 in relation to the audit; and
- (ii) No contraventions of any applicable code of professional conduct in relation to the audit.

**Hall Chadwick Melbourne Audit  
Chartered Accountants  
Level 14, 440 Collins Street  
MELBOURNE VIC 3000**

---

**Partner: David Lissauer**

**Date:**

**Sun Pharma ANZ Pty Ltd**

**Contents**

**31 March 2021**

Statement of profit or loss and other comprehensive income	5
Statement of financial position	6
Statement of changes in equity	7
Statement of cash flows	8
Notes to the financial statements	9
Directors' declaration	20
Independent auditor's report to the members of Sun Pharma ANZ Pty Ltd	21

**General information**

The financial statements cover Sun Pharma ANZ Pty Ltd as an individual entity. The financial statements are presented in Australian dollars, which is Sun Pharma ANZ Pty Ltd's functional and presentation currency.

Sun Pharma ANZ Pty Ltd is a company limited by shares, incorporated and domiciled in Australia.

**Sun Pharma ANZ Pty Ltd**  
**Statement of profit or loss and other comprehensive income**  
**For the year ended 31 March 2021**

	Note	2021 \$	2020 \$
<b>Revenue</b>	3	53,332,396	47,897,116
Other income	4	1,334,364	939,105
Interest revenue calculated using the effective interest method		125	49
<b>Expenses</b>			
Cost of goods sold		(41,094,102)	(36,133,017)
Employee benefits expenses		(6,437,078)	(5,551,015)
Depreciation and amortisation expenses		(230,929)	(224,122)
Other expenses		(163,564)	(356,153)
Finance costs		(394,361)	(399,384)
Distribution		(2,724,066)	(2,813,929)
Marketing expenses		(277,098)	(68,536)
Occupancy expenses		(69,945)	(91,178)
Pharmaceutical license fees		(46,870)	(27,745)
Administration expenses		(338,998)	(559,570)
<b>Profit before income tax</b>		2,889,874	2,611,621
Current tax		-	-
Deferred tax credit/(expense)		5,009,049	-
<b>Total income tax credit/(expense)</b>	5	<u>5,009,049</u>	<u>-</u>
<b>Profit after income tax for the year attributable to the owners of Sun Pharma ANZ Pty Ltd</b>		7,898,923	2,611,621
Other comprehensive income for the year, net of tax		<u>-</u>	<u>-</u>
<b>Total comprehensive income for the year attributable to the owners of Sun Pharma ANZ Pty Ltd</b>		<u><u>7,898,923</u></u>	<u><u>2,611,621</u></u>

*The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes*

**Sun Pharma ANZ Pty Ltd**  
**Statement of financial position**  
**As at 31 March 2021**

	Note	2021 \$	2020 \$
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents	6	3,379,789	2,343,437
Trade and other receivables	7	13,429,242	12,885,865
Inventories	8	19,649,462	16,573,864
Other	9	77,362	202,047
Total current assets		<u>36,535,855</u>	<u>32,005,213</u>
<b>Non-current assets</b>			
Property, plant and equipment	10	97,726	157,816
Right-of-use assets	11	228,158	389,210
Intangibles	12	1,057,229	530,022
Deferred tax	13	5,009,049	-
Total non-current assets		<u>6,392,162</u>	<u>1,077,048</u>
<b>Total assets</b>		<u>42,928,017</u>	<u>33,082,261</u>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables	14	19,859,395	18,096,120
Borrowings	15	14,645,538	14,645,538
Lease liabilities	16	171,439	158,996
Employee benefits	17	646,855	462,919
Provisions	18	180,000	180,000
Other	19	1,983,875	1,872,315
Total current liabilities		<u>37,487,102</u>	<u>35,415,888</u>
<b>Non-current liabilities</b>			
Lease liabilities	20	74,054	244,962
Employee benefits	21	273,783	227,256
Total non-current liabilities		<u>347,837</u>	<u>472,218</u>
<b>Total liabilities</b>		<u>37,834,939</u>	<u>35,888,106</u>
<b>Net assets/(liabilities)</b>		<u>5,093,078</u>	<u>(2,805,845)</u>
<b>Equity</b>			
Issued capital	22	17,400,000	17,400,000
Accumulated losses		<u>(12,306,922)</u>	<u>(20,205,845)</u>
<b>Total equity/(deficiency)</b>		<u>5,093,078</u>	<u>(2,805,845)</u>

*The above statement of financial position should be read in conjunction with the accompanying notes*

**Sun Pharma ANZ Pty Ltd**  
**Statement of changes in equity**  
**For the year ended 31 March 2021**

	<b>Issued capital \$</b>	<b>Retained profits \$</b>	<b>Total deficiency in equity \$</b>
Balance at 1 April 2019	17,400,000	(22,817,466)	(5,417,466)
Profit after income tax expense for the year	-	2,611,621	2,611,621
Other comprehensive income for the year, net of tax	-	-	-
Total comprehensive income for the year	-	2,611,621	2,611,621
Balance at 31 March 2020	<u>17,400,000</u>	<u>(20,205,845)</u>	<u>(2,805,845)</u>

	<b>Issued capital \$</b>	<b>Retained profits \$</b>	<b>Total equity \$</b>
Balance at 1 April 2020	17,400,000	(20,205,845)	(2,805,845)
Profit after income tax benefit for the year	-	7,898,923	7,898,923
Other comprehensive income for the year, net of tax	-	-	-
Total comprehensive income for the year	-	7,898,923	7,898,923
Balance at 31 March 2021	<u>17,400,000</u>	<u>(12,306,922)</u>	<u>5,093,078</u>

*The above statement of changes in equity should be read in conjunction with the accompanying notes*



**Sun Pharma ANZ Pty Ltd**  
**Statement of cash flows**  
**For the year ended 31 March 2021**

	Note	2021 \$	2020 \$
<b>Cash flows from operating activities</b>			
Receipts from customers (inclusive of GST)		59,400,895	58,311,971
Payments to suppliers and employees (inclusive of GST)		<u>(57,274,847)</u>	<u>(56,068,580)</u>
		2,126,048	2,243,391
Interest received		125	49
Interest paid		<u>(386,073)</u>	<u>(387,130)</u>
Net cash from operating activities		<u>1,740,100</u>	<u>1,856,310</u>
<b>Cash flows from investing activities</b>			
Payments for property, plant and equipment	10	(9,788)	(33,574)
Payments for intangibles	12	<u>(527,207)</u>	<u>(530,022)</u>
Net cash used in investing activities		<u>(536,995)</u>	<u>(563,596)</u>
<b>Cash flows from financing activities</b>			
Interest of lease liabilities paid		(8,631)	(12,253)
Repayment of lease liabilities		<u>(158,122)</u>	<u>(146,305)</u>
Net cash used in financing activities		<u>(166,753)</u>	<u>(158,558)</u>
Net increase in cash and cash equivalents		1,036,352	1,134,156
Cash and cash equivalents at the beginning of the financial year		<u>2,343,437</u>	<u>1,209,281</u>
Cash and cash equivalents at the end of the financial year	6	<u><u>3,379,789</u></u>	<u><u>2,343,437</u></u>

*The above statement of cash flows should be read in conjunction with the accompanying notes*

## **Note 1. Significant accounting policies**

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

### **New or amended Accounting Standards and Interpretations adopted**

The company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

### **Going concern**

The financial statements have been prepared on a going concern basis.

The ability of the Company to continue as going concern is dependent upon the ongoing financial support from its parent entity to the level required by the company to allow it to fulfill all obligations as and when they fall due for a period of no less than twelve months from the date of signing these financial statements. The reliance on the parent entity support gives rise to a material uncertainty which may affect the company's ability to continue as a going concern. The parent entity has confirmed in writing that it will provide ongoing financial support, including that it will not call for repayment outstanding balances at 31 March 2021, unless the Company is able to financially make such repayments without impairing its ability to conduct its normal business operations and pay other liabilities.

Sun Pharma ANZ Pty Ltd (the company) is a company incorporated and domiciled in Australia. The parent company is Sun Pharma (Netherlands) B.V, a company incorporated in Netherlands.

The company is primarily involved in the supply of pharmaceutical products.

### **Basis of preparation**

In the directors' opinion, the company is not a reporting entity because there are no users dependent on general purpose financial statements.

These are special purpose financial statements that have been prepared for the purposes of complying with the Corporations Act 2001 requirements to prepare and distribute financial statements to the owners of Sun Pharma ANZ Pty Ltd. The directors have determined that the accounting policies adopted are appropriate to meet the needs of the owners of Sun Pharma ANZ Pty Ltd.

These financial statements have been prepared in accordance with the recognition and measurement requirements specified by the Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the disclosure requirements of AASB 101 'Presentation of Financial Statements', AASB 107 'Statement of Cash Flows', AASB 108 'Accounting Policies, Changes in Accounting Estimates and Errors', AASB 1048 'Interpretation of Standards' and AASB 1054 'Australian Additional Disclosures', as appropriate for for-profit oriented entities.

### *Historical cost convention*

The financial statements have been prepared under the historical cost convention, except for, where applicable, the revaluation of financial assets and liabilities at fair value through profit or loss, financial assets at fair value through other comprehensive income, investment properties, certain classes of property, plant and equipment and derivative financial instruments.

### *Critical accounting estimates*

The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the company's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 2.

### **Revenue recognition**

The company recognises revenue as follows:

#### *Sale of goods*

Revenue from the sale of goods is recognised at the point in time when the customer obtains control of the goods, which is generally at the time of delivery.

**Note 1. Significant accounting policies (continued)**

*Interest*

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

*Other revenue*

Other revenue is recognised when it is received or when the right to receive payment is established.

**Income tax**

The income tax expense or benefit for the period is the tax payable on that period's taxable income based on the applicable income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognised for prior periods, where applicable.

Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to be applied when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for:

- When the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or
- When the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future.

Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date. Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable that there are future taxable profits available to recover the asset.

Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously.

**Current and non-current classification**

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the company's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the company's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

Deferred tax assets and liabilities are always classified as non-current.

**Cash and cash equivalents**

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

**Trade and other receivables**

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any provision for impairment. Trade receivables are generally due for settlement within 60 days.

**Note 1. Significant accounting policies (continued)**

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

**Inventories**

Finished goods are stated at the lower of cost and net realisable value on a weighted moving average basis. Cost comprises of purchase and delivery costs, net of rebates and discounts received or receivable.

Stock in transit is stated at the lower of cost and net realisable value. Cost comprises of purchase, net of rebates and discounts received or receivable.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

**Property and equipment**

Property and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation is calculated on a straight-line basis to write off the net cost of each item of property and equipment over their expected useful lives as follows:

Office equipment	3 - 5 years
Fixture and fittings	5 years

The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date.

An item of property and equipment is derecognised upon disposal or when there is no future economic benefit to the company. Gains and losses between the carrying amount and the disposal proceeds are taken to profit or loss. Any revaluation surplus reserve relating to the item disposed of is transferred directly to retained profits.

**Right-of-use assets**

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the company expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

The company has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

**Trade and other payables**

These amounts represent liabilities for goods and services provided to the company prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

**Borrowings**

Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They are subsequently measured at amortised cost using the effective interest method.

**Note 1. Significant accounting policies (continued)**

**Lease liabilities**

A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the company's incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred.

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of-use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.

**Finance costs**

Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred.

**Provisions**

Provisions are recognised when the company has a present (legal or constructive) obligation as a result of a past event, it is probable the company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current pre-tax rate specific to the liability. The increase in the provision resulting from the passage of time is recognised as a finance cost.

**Employee benefits**

*Short-term employee benefits*

Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to be settled wholly within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled.

*Other long-term employee benefits*

The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date are measured at the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

**Fair value measurement**

When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market.

Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

**Issued capital**

Ordinary shares are classified as equity.

**Note 1. Significant accounting policies (continued)**

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

**Goods and Services Tax ('GST') and other similar taxes**

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

**New Accounting Standards and Interpretations not yet mandatory or early adopted**

Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the company for the annual reporting period ended 31 March 2021. The company has not yet assessed the impact of these new or amended Accounting Standards and Interpretations.

**Note 2. Critical accounting judgements, estimates and assumptions**

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

*Allowance for expected credit losses*

The allowance for expected credit losses assessment requires a degree of estimation and judgement. It is based on the lifetime expected credit loss, grouped based on days overdue, and makes assumptions to allocate an overall expected credit loss rate for each group. These assumptions include recent sales experience and historical collection rates.

*Estimation of useful lives of assets*

The company determines the estimated useful lives and related depreciation and amortisation charges for its property, plant and equipment and finite life intangible assets. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

*Income tax*

The company is subject to income taxes in the jurisdictions in which it operates. Significant judgement is required in determining the provision for income tax. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain. The company recognises liabilities for anticipated tax audit issues based on the company's current understanding of the tax law. Where the final tax outcome of these matters is different from the carrying amounts, such differences will impact the current and deferred tax provisions in the period in which such determination is made.

*Recovery of deferred tax assets*

Deferred tax assets are recognised for deductible temporary differences only if the company considers it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

**Note 2. Critical accounting judgements, estimates and assumptions (continued)**

*Employee benefits provision*

As discussed in note 1, the liability for employee benefits expected to be settled more than 12 months from the reporting date are recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and pay increases through promotion and inflation have been taken into account.

**Note 3. Revenue**

	2021 \$	2020 \$
Sales	<u>53,332,396</u>	<u>47,897,116</u>

**Note 4. Other income**

	2021 \$	2020 \$
Other income cross charges to related parties	905,022	913,722
Other income	<u>429,342</u>	<u>25,383</u>
Other income	<u>1,334,364</u>	<u>939,105</u>

**Note 5. Income tax benefit**

	2021 \$	2020 \$
<i>Numerical reconciliation of income tax benefit and tax at the statutory rate</i>		
Profit before income tax benefit	<u>2,889,874</u>	<u>2,611,621</u>
Tax at the statutory tax rate of 30%	866,962	783,486
Prior year tax losses not recognised now recouped	(866,962)	(783,486)
Prior year temporary differences not recognised now recognised	<u>5,009,049</u>	<u>-</u>
Income tax benefit	<u>5,009,049</u>	<u>-</u>

**Note 6. Current assets - cash and cash equivalents**

	2021 \$	2020 \$
Cash at bank	<u>3,379,789</u>	<u>2,343,437</u>

**Sun Pharma ANZ Pty Ltd**  
**Notes to the financial statements**  
**31 March 2021**

**Note 7. Current assets - trade and other receivables**

	<b>2021</b>	<b>2020</b>
	<b>\$</b>	<b>\$</b>
Trade receivables	18,715,237	19,436,528
Less: Provision for customer rebates, discounts & doubtful debts	<u>(5,910,515)</u>	<u>(8,918,587)</u>
	<u>12,804,722</u>	<u>10,517,941</u>
Other receivables - related parties	<u>624,520</u>	<u>2,367,924</u>
	<u><u>13,429,242</u></u>	<u><u>12,885,865</u></u>

**Note 8. Current assets - inventories**

	<b>2021</b>	<b>2020</b>
	<b>\$</b>	<b>\$</b>
Finished goods - at cost	18,051,356	16,714,768
Less: Provision for impairment	<u>(607,173)</u>	<u>(1,104,269)</u>
	<u>17,444,183</u>	<u>15,610,499</u>
Stock in transit - at cost	<u>2,205,279</u>	<u>963,365</u>
	<u><u>19,649,462</u></u>	<u><u>16,573,864</u></u>

**Note 9. Current assets - other**

	<b>2021</b>	<b>2020</b>
	<b>\$</b>	<b>\$</b>
Prepayments	72,058	198,217
Advance to employees	5,304	-
Other deposits	<u>-</u>	<u>3,830</u>
	<u><u>77,362</u></u>	<u><u>202,047</u></u>



**Sun Pharma ANZ Pty Ltd**  
**Notes to the financial statements**  
**31 March 2021**

**Note 10. Non-current assets - property, plant and equipment**

	<b>2021</b>	<b>2020</b>
	<b>\$</b>	<b>\$</b>
Leasehold improvements - at independent valuation	135,150	135,150
Less: Accumulated depreciation	<u>(92,073)</u>	<u>(61,988)</u>
	43,077	73,162
Fixtures and fittings - at cost	102,005	102,005
Less: Accumulated depreciation	<u>(70,857)</u>	<u>(49,585)</u>
	31,148	52,420
Computer equipment - at cost	213,984	204,787
Less: Accumulated depreciation	<u>(192,269)</u>	<u>(174,278)</u>
	21,715	30,509
Office equipment - at cost	9,779	9,188
Less: Accumulated depreciation	<u>(7,993)</u>	<u>(7,463)</u>
	1,786	1,725
	<u>97,726</u>	<u>157,816</u>

**Note 11. Non-current assets - right-of-use assets**

	<b>2021</b>	<b>2020</b>
	<b>\$</b>	<b>\$</b>
Office equipment - right-of-use	550,263	550,262
Less: Accumulated depreciation	<u>(322,105)</u>	<u>(161,052)</u>
	<u>228,158</u>	<u>389,210</u>

**Note 12. Non-current assets - intangibles**

	<b>2021</b>	<b>2020</b>
	<b>\$</b>	<b>\$</b>
Licence - at cost	<u>1,057,229</u>	<u>530,022</u>

**Note 13. Non-current assets - deferred tax**

	<b>2021</b>	<b>2020</b>
	<b>\$</b>	<b>\$</b>
Deferred tax asset	<u>5,009,049</u>	<u>-</u>

**Sun Pharma ANZ Pty Ltd**  
**Notes to the financial statements**  
**31 March 2021**

**Note 14. Current liabilities - trade and other payables**

	<b>2021</b>	<b>2020</b>
	<b>\$</b>	<b>\$</b>
Trade payables	404,099	519,590
Payables to related parties	19,455,296	17,576,530
	<u>19,859,395</u>	<u>18,096,120</u>

**Note 15. Current liabilities - borrowings**

	<b>2021</b>	<b>2020</b>
	<b>\$</b>	<b>\$</b>
Inter-company loans	<u>14,645,538</u>	<u>14,645,538</u>

**Note 16. Current liabilities - lease liabilities**

	<b>2021</b>	<b>2020</b>
	<b>\$</b>	<b>\$</b>
Lease liability	<u>171,439</u>	<u>158,996</u>

**Note 17. Current liabilities - employee benefits**

	<b>2021</b>	<b>2020</b>
	<b>\$</b>	<b>\$</b>
Employee benefits	<u>646,855</u>	<u>462,919</u>

**Note 18. Current liabilities - provisions**

	<b>2021</b>	<b>2020</b>
	<b>\$</b>	<b>\$</b>
Sales returns	<u>180,000</u>	<u>180,000</u>

**Note 19. Current liabilities - other**

	<b>2021</b>	<b>2020</b>
	<b>\$</b>	<b>\$</b>
BAS Payable	703,096	817,082
Superannuation Payable	49,029	29,389
Redistribution Accrual	158,927	212,428
Other payables	64,288	94,969
Accrued expenses	1,008,535	718,447
	<u>1,983,875</u>	<u>1,872,315</u>

**Sun Pharma ANZ Pty Ltd**  
**Notes to the financial statements**  
**31 March 2021**

**Note 20. Non-current liabilities - lease liabilities**

	2021 \$	2020 \$
Lease liability	<u>74,054</u>	<u>244,962</u>

**Note 21. Non-current liabilities - employee benefits**

	2021 \$	2020 \$
Employee benefits	<u>273,783</u>	<u>227,256</u>

**Note 22. Equity - issued capital**

	2021 \$	2020 \$
Ordinary shares - fully paid	9,200,000	9,200,000
Preference shares - fully paid	<u>8,200,000</u>	<u>8,200,000</u>
	<u>17,400,000</u>	<u>17,400,000</u>

*Ordinary shares*

Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

**Note 23. Equity - dividends**

There were no dividends paid, recommended or declared during the current or previous financial year.

**Note 24. Application of AASB 16 Leases**

	2021 \$	2020 \$
<i>Operating lease commitments</i>		
Committed at the reporting date but not recognised as liabilities, payable:		
Operating lease commitments 01 April 2019	-	575,124
Operating lease commitments discount based on incremental borrowing rate of 2.6%	<u>-</u>	<u>(24,862)</u>
Lease liability 1 April 2019	<u>-</u>	<u>550,262</u>

As per the requirements of AASB 16 'Leases', lease liability has been fully recognized in the Balance Sheet beginning from mandatory application date, 1 April 2019. This means that operating lease commitment note is not required from this year.

**Note 25. Economic dependency**

Sun Pharma ANZ Pty Ltd is economically dependent on the related party, Sun Pharma Industries Ltd., to provide inventory and is also dependent on Sun Pharma (Netherlands) B.V for financial support to continue its operation.

**Note 26. Events after the reporting period**

No matter or circumstance has arisen since 31 March 2021 that has significantly affected, or may significantly affect the company's operations, the results of those operations, or the company's state of affairs in future financial years.

**Sun Pharma ANZ Pty Ltd**  
**Directors' declaration**  
**31 March 2021**

In the directors' opinion:

- the company is not a reporting entity because there are no users dependent on general purpose financial statements. Accordingly, as described in note 1 to the financial statements, the attached special purpose financial statements have been prepared for the purposes of complying with the Corporations Act 2001 requirements to prepare and distribute financial statements to the owners of Sun Pharma ANZ Pty Ltd;
- the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards as described in note 1 to the financial statements, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the company's financial position as at 31 March 2021 and of its performance for the financial year ended on that date; and
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the directors

---

Akshay Sethi  
Head of Finance, Director

Date:

**SUN PHARMA ANZ PTY LTD**  
**ABN 17 110 871 826**

**INDEPENDENT AUDITOR'S REPORT**  
**TO THE MEMBERS OF SUN PHARMA ANZ PTY LTD**

**Report on the Audit of the Financial Report**

**Opinion**

We have audited the financial report of Sun Pharma ANZ Pty Ltd (the Company), which comprises the statement of financial position as at 31 March 2021, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, and the directors' declaration.

In our opinion, the accompanying financial report of Sun Pharma ANZ Pty Ltd, is in accordance with the *Corporations Act 2001*, including:

- (a) giving a true and fair view of the company's financial position as at 31 March 2021 and of its financial performance for the year then ended; and
- (b) complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

**Basis for Opinion**

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of a Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of the Company would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Responsibilities of the Directors for the Financial Report**

The directors of the Company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

### **Auditor's Responsibilities for the Audit of the Financial Report**

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

### **Information Other than the Financial Report and Auditor's Report Thereon**

The directors are responsible for the other information. The other information comprises the information included in the annual report for the year ended 31 March 2021, but does not include the financial report and our auditor's report thereon. Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon. In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

---

Partner: David Lissauer

**Hall Chadwick Melbourne Audit  
Level 14, 440 Collins Street  
MELBOURNE VIC 3000**

**Date:**